Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TRAW)

Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes

GlobeNewswire March 25, 2019

Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

GlobeNewswire March 19, 2019

Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA

GlobeNewswire March 12, 2019

Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City

GlobeNewswire February 4, 2019

Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City

GlobeNewswire January 31, 2019

Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL

GlobeNewswire January 22, 2019

Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer

GlobeNewswire January 15, 2019

Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)

GlobeNewswire January 2, 2019

Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco

GlobeNewswire December 31, 2018

Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel

GlobeNewswire December 10, 2018

Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting

GlobeNewswire December 3, 2018

Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018

GlobeNewswire November 13, 2018

Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO)

GlobeNewswire November 7, 2018

Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition

GlobeNewswire November 5, 2018

Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results

GlobeNewswire November 1, 2018

Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark

GlobeNewswire October 29, 2018

Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib

GlobeNewswire October 17, 2018

Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco

GlobeNewswire October 10, 2018

Onconova Therapeutics Announces Reverse Stock Split

GlobeNewswire September 25, 2018

Cancer Immunotherapy Treatment Market on the Rise as R&D Increases

PR Newswire September 21, 2018